Editorial use only.
Pazopanib cancer drug. Votrient. Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis, the production of new blood vessels. It is used to treat renal cell (kidney) carcinoma and soft tissue sarcoma.
Model release not required. Property release not required.